http://biz.yahoo.com/e/071220/alrx.o...
Two things I noticed the "License fees and royalties totaled $81,602" from sales of Indaflex in Mexico 3 times last year. So the demand is there. Also research costs are down as expected since they are off loading cost to other companies.
This does not mean too much since 2008 is the pivotal year for Alpharx. 3-4 products going to FDA and the milestone payments.